Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ZLAB vs HCM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HCM Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 7–2 Matrix Metrics)

HCM Overall Winner 6-Pillar Tally: ZLAB 1 – 4 HCM (1 Tie) Matrix Metrics: ZLAB 2 – 7 HCM

As of Nov 16, 2026, HUTCHMED (China) Limited (HCM) is the stronger overall head-to-head candidate over Zai Lab Limited (ZLAB) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ZLAB carries a Unified Composite Score of 47.4/100 (HOLD) at $23.74 (N/M Forward P/E, -63.0% operating margin), whereas HCM carries 37.9/100 (SELL) at $14.69 (N/M Forward P/E, -6.3% operating margin).

  • Composite vs. Pillar Nuance: While ZLAB currently prints a higher short-term Unified Composite Score (47.4/100 HOLD vs. HCM 37.9/100 SELL), HCM captures the overall institutional head-to-head verdict (7–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-6.3% vs. -63.0% operating margin) and revenue trajectory (+0.2% vs. -6.8% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ZLAB vs HCM
ZLAB NASDAQ
Zai Lab Limited American Depositary Shares
Pharmaceutical Preparations
$23.74
-3.5% 1D
Market Cap $3.0B
TTM Revenue $442M
Forward P/E N/M
Beta / 30D Vol 1.19β · 78% Vol
Unified Composite Score
47.4 / 100 HOLD
Tech 25.0 Fund 39.0 Flow 50.0 Mom 53.5
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.1 · SMA20: $23.97 · SMA50: $24.57
HCM NASDAQ Head-to-Head Winner
HUTCHMED (China) Limited American Depositary Shares
Pharmaceutical Preparations
$14.69
-1.44% 1D
Market Cap $2.6B
TTM Revenue $549M
Forward P/E N/M
Beta / 30D Vol 0.61β · 45% Vol
Unified Composite Score
37.9 / 100 SELL
Tech 8.0 Fund 30.0 Flow 50.0 Mom 36.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.3% over 20 days), RSI 55
RSI-14: 55.0 · SMA20: $14.29 · SMA50: $14.07

6-Pillar Scorecard Institutional Category Breakdown (ZLAB 1 – 4 HCM)

Columns: Metric · ZLAB · HCM
1. Valuation Multiples HCM
Forward P/E N/M N/M
Trailing P/E N/M 148.3x
PEG Ratio N/M N/M
EV / Revenue 6.8x 4.7x
2. Growth & Scale HCM
Revenue Growth (YoY) -6.8% +0.2%
Earnings Growth (YoY) +0.0% -96.5%
TTM Revenue (USD) $442M $549M
Market Cap $3.0B $2.6B
3. Profitability & Quality HCM
Gross Margin 0.6% 13.3%
Operating Margin -63.0% -6.3%
Net Profit Margin -44.9% 3.3%
Return on Equity (ROE) -30.0% 1.5%
4. Balance Sheet & Cash Flow HCM
Cash Generation (TTM) -$262M EBITDA -$21M EBITDA
Cash Flow Margin -59.3% EBITDA Mgn -3.7% EBITDA Mgn
Net Cash / Leverage $5.01 Book/Sh · -30.0% ROE $7.25 Book/Sh · 1.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 58.4% (58th %ile) 82.7% (73rd %ile)
Put/Call OI Skew Thin ADR Chain Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat ZLAB
OpEx & R&D Intensity 63.6% of Rev ($281M) 19.6% of Rev ($108M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ZLAB (2) vs HCM (7)
Institutional Metric ZLAB HCM Criterion Row Edge
Market Capitalization
Scale
$3.0B $2.6B Larger Scale ZLAB
Trailing P/E Ratio
Valuation
N/M 148.3x Lower Multiple HCM
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-6.8% +0.2% Higher Growth HCM
Operating Margin (TTM)
Profitability
-63.0% -6.3% Higher Margin HCM
Net Profit Margin
Profitability
-44.9% 3.3% Higher Margin HCM
Return on Equity (ROE)
Capital Efficiency
-30.0% 1.5% Higher ROE HCM
52-Week Range Position
Momentum
60% ($16–$29) 75% ($10–$16) Stronger Trend HCM
Beta / 30D Volatility
Risk Regime
1.19β · 78% Vol 0.61β · 45% Vol Lower Realized Risk HCM
Unified Institutional Score
Composite Signal
47.4 / 100 (HOLD) 37.9 / 100 (SELL) Higher Composite ZLAB
Trailing 12M Revenue (USD)
Operating Scale
$442M $549M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
0.6% 13.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.8x EV/Rev N/M PEG · 4.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$262M EBITDA ($5.01 Book/Sh · -30.0% ROE) -$21M EBITDA ($7.25 Book/Sh · 1.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon HCM +2.15 pp
ZLAB: +2.37% · HCM: +4.52%
3M Horizon HCM +23.34 pp
ZLAB: -7.16% · HCM: +16.18%
6M Horizon ZLAB +2.98 pp
ZLAB: +25.87% · HCM: +22.89%
1Y Horizon ZLAB +12.51 pp
ZLAB: +9.25% · HCM: -3.26%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ZLAB vs HCM. Trailing 12-month operating profitability (ZLAB -63.0% vs HCM -6.3%) and valuation multiples (ZLAB N/M vs HCM N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ZLAB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$442M
Gross Margin0.6%
Op. Margin-63.0%
ROE / Fwd P/E-30.0% · N/M
HCM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$549M
Gross Margin13.3%
Op. Margin-6.3%
ROE / Fwd P/E1.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ZLAB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 58.4%
IV Percentile 58th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ZLAB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
HCM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 82.7%
IV Percentile 73rd %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact HCM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ZLAB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.0B market capitalization and -63.0% operating margin.
OpEx & R&D Reinvestment 63.6% of Rev ($281M)
90D Engineering Disclosures 0 Published
HCM Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.6B market capitalization and -6.3% operating margin.
OpEx & R&D Reinvestment 19.6% of Rev ($108M)
90D Engineering Disclosures 0 Published

Investor FAQ ZLAB vs HCM Key Questions & Quantitative Answers

As of Nov 16, 2026, HUTCHMED (China) Limited (HCM) is the stronger overall head-to-head candidate over Zai Lab Limited (ZLAB) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ZLAB carries a Unified Composite Score of 47.4/100 (HOLD) at $23.74 (N/M Forward P/E, -63.0% operating margin), whereas HCM carries 37.9/100 (SELL) at $14.69 (N/M Forward P/E, -6.3% operating margin). Composite vs. Pillar Nuance: While ZLAB currently prints a higher short-term Unified Composite Score (47.4/100 HOLD vs. HCM 37.9/100 SELL), HCM captures the overall institutional head-to-head verdict (7–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-6.3% vs. -63.0% operating margin) and revenue trajectory (+0.2% vs. -6.8% YoY).

HCM leads the Growth & Scale pillar: ZLAB posts -6.8% YoY revenue growth and +0.0% YoY earnings growth on $442M TTM revenue (0.6% gross margin, -63.0% operating margin), compared with HCM at +0.2% YoY revenue growth and -96.5% YoY earnings growth on $549M TTM revenue (13.3% gross margin, -6.3% operating margin). On trailing 12-month operating scale, ZLAB generates $442M in USD-normalized revenue versus $549M for HCM. In operating R&D and SG&A reinvestment, ZLAB deploys 63.6% of Rev ($281M) (0 90-day corporate R&D disclosures) versus 19.6% of Rev ($108M) (0 disclosures) for HCM.

HCM screens cheaper on headline valuation multiples. ZLAB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.8x EV/Revenue (-59.3% EBITDA margin), whereas HCM trades at N/M Forward P/E, 148.3x Trailing P/E, N/M PEG, and 4.7x EV/Revenue (-3.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ZLAB (-30.0% ROE) versus HCM (1.5% ROE) capital efficiency.

In options market volatility and institutional positioning, ZLAB carries 58.4% implied volatility (58th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 78% Vol realized risk). By comparison, HCM carries 82.7% implied volatility (73rd %ile, Elevated (60th–80th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.61β · 45% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

HUTCHMED (China) Limited American Depositary Shares (HCM) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.